MO-BLUE-YONDER
To improve customer experience and satisfaction, retailers are looking to offer a personalized assortment and easy to navigate display of products in their stores. That’s why Nestlé Purina Petcare, the leading manufacturer of pet care products, has successfully implemented Blue Yonder’s category management solution integrated with 3DVR Solutions’ (3DVRS) 3D virtual reality technology to assist its retail partners with better merchandizing of their store shelfs.
Purina is the No. 1 pet care company in the U.S. It offers more than 20 brands in the U.S., feeding 65 million dogs and 51 million cats annually. Purina provides its retail partners with planograms that design shelfs aimed at merchandizing products to meet customer needs. However, with travel restricted during the COVID-19 lockdowns, it needed an alternate way for its associates to work with its retail partners remotely to replicate critical tasks that would otherwise be performed in front of a physical planogram or in store.
Enter 3DVRS’ innovative Retail Visualisation Suite (RVS) Virtual Reality (VR) Headset solution, which combines planogram data from Blue Yonder with a cutting-edge virtual reality headset provider to deliver a fully interactive, networked avatar-based merchandising solution. This integrated solution brings people from all over the globe into a common unique headset experience in the metaverse where they can plan, present and interact. The integrated solution is now also available to other companies who are looking to solve similar challenges.
Thanks to this integrated solution, Purina has achieved some key benefits:
- Removed the need to be in a physical store to make shelfing decisions by bringing people together in the metaverse, which has in turn reduced environmental impact from less travel and decreased training costs.
- Reduced time to merchandise a shelf via an interactive planogram before moving real product.
- Incorporated true-to-life factors into shelf planning.
- Partner with retailers to enhance the customer journey in store and share global best practices.
“3DVRS’ integration with Blue Yonder delivers flexibility, speed and scale, giving us the ability to effectively deploy across the business. The evolution from virtual reality on the desktop to network avatars in the RVS VR Headset solution has been seamless. We can now hold meetings virtually in the metaverse, interact with layouts, products, and store innovations, allowing us to be right at the cutting edge,” said Gene Feldman, training manager, Purina.
Together, Blue Yonder's category management and 3DVRS’ RVS VR Headset solutions have enabled Purina’s retail partners to make faster, more accurate and localized space allocation decisions to help their customers find the products they need more easily while guaranteeing a better shopping and service experience.
“Purina is a fantastic partner to innovate with as they are always looking to the latest technology to give their business the edge. The challenges they presented pushed technological boundaries. Our integration with Blue Yonder gives us the platform to support large enterprises such as Purina. It’s great to bring new tech to the market that makes a real difference. It’s amazing what we have achieved together already, but I sense there's a lot more to come,” said Nigel Hemer, CEO and founder, 3DVR Solutions.
“Working with 3DVRS has allowed us to bring Blue Yonder’s planograms to life in the metaverse where users can merchandise, analyze, interact, and meet as avatars to design shelfs that meet customers’ needs. This is cutting-edge technology at its finest and Purina was one of the first companies to benefit from it. By creating a culture of innovation and thought leadership throughout the organization, Purina is building a great place to work for both their associates and retail partners,” said Phillip Teschemacher, corporate vice president, Manufacturing - EMEA, Blue Yonder.
Additional Resources:
- Learn more about Blue Yonder's category management solution
- Learn how to achieve smarter Category Management with Blue Yonder
About Nestlé Purina PetCare
Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations.
Purina manufactures some of the world's most trusted and popular pet care products, including Purina Cat Chow, Purina ONE, Pro Plan, Fancy Feast and Tidy Cats. Our more than 8,700 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 51 million dogs and 65 million cats every year. More than 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition. Purina promotes responsible pet care through our scientific research, our products and our support for pet-related organizations.
Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive. Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.
About 3DVR Solutions
As a global Blue Yonder technology partner for 10 years, 3DVRS leverages Blue Yonder planogram and store CAD data to create highly visual 3D environments, enabling retailers & suppliers to plan, design and respond to rapidly changing market conditions. The unique design of 3DVR’s virtual reality solutions deliver automation, speed and scale without inherent dependencies and costs. 3DVR support Blue Yonder customers around the globe, including those on Microsoft Azure. www.3dvrs.com
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformations and omni-channel commerce fulfillment. Our end-to-end, cognitive business platform enables retailers, manufacturers and logistics providers to best fulfill customer demand from planning through delivery. With Blue Yonder, you'll unify your data, supply chain and retail commerce operations to unlock new business opportunities and drive automation, control and orchestration to enable more profitable, sustainable business decisions. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005378/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom